	US 12,239,666 B2
	Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
Amer A. Beg, Tampa, FL (US); Scott J. Antonia, Durham, NC (US); and Mark J. Cantwell, Meadow Vista, CA (US)
Assigned to H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. INC., Tampa, FL (US); and MEMGEN, INC., Houston, TX (US)
Appl. No. 17/253,927
Filed by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US); and MEMGEN, INC., Houston, TX (US)
PCT Filed Jun. 18, 2019, PCT No. PCT/US2019/037753 § 371(c)(1), (2) Date Dec. 18, 2020, PCT Pub. No. WO2019/246111, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/687,076, filed on Jun. 19, 2018.
Prior Publication US 2021/0268090 A1, Sep. 2, 2021
Int. Cl. A61K 35/28 (2015.01); A61K 35/761 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/56 (2006.01); C07K 14/705 (2006.01); C12N 5/0784 (2010.01); C12N 7/00 (2006.01)

CPC A61K 35/28 (2013.01) [A61K 35/761 (2013.01); A61K 39/4615 (2023.05); A61K 39/4622 (2023.05); A61K 39/464441 (2023.05); A61K 39/464838 (2023.05); A61P 35/00 (2018.01); C07K 14/56 (2013.01); C07K 14/70578 (2013.01); C12N 5/0639 (2013.01); C12N 7/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/585 (2013.01); A61K 2239/57 (2023.05); C12N 2510/00 (2013.01); C12N 2710/10321 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01)]

8 Claims

1. An oncolytic virus comprising:

(i) a nucleic acid sequence encoding a type I interferon, wherein the type I interferon is: IFNα comprising at least 80% sequence identity to the human IFNα (SEQ ID NO: 1), IFNβ comprising at least 80% sequence identity to the human IFNβ (SEQ ID NO: 2), IFNε comprising at least 80% sequence identity to the human IFN& (SEQ ID NO: 3), IFNκ comprising at least 80% sequence identity to the human IFNκ (SEQ ID NO: 4), or IFNω comprising at least 80% sequence identity to the human IFN (SEQ ID NO: 5);

(ii) a nucleic acid sequence encoding a CD40-L, which comprises at least 80% sequence identity to a chimeric CD40-L having a sequence selected from SEQ ID NOs: 7 to 18;

(iii) a CMV promoter sequence operatively linked to the nucleic acid sequence encoding the CD40L such that expression of the CD40L is directed by the CMV promoter; and

(iv) an SV40 promoter sequence operatively linked to the nucleic acid sequence encoding the type I interferon such that expression of the type I interferon is directed by the SV40 promoter, wherein the oncolytic virus is recombinant adenovirus.